Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 17 Triple Negative Breast Neoplasms 9 Urinary Bladder Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplastic Cells, Circulating 1 Multiple Myeloma 1 Lymphoma, T-Cell, Peripheral 1 Hormone Receptor Positive HER-2 Negative Breast Cancer 1 HR-positive,HER2-negative Breast Cancer 1 HR+/HER2- Breast Cancer 1 HER2-negative Early Breast Cancer 1 HER2-negative Breast Cancer 1 HER2 Positive Early Breast Cancer 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Adenoid Cystic 1

Interventions

Paclitaxel 10 Carboplatin 6 Bevacizumab 5 pembrolizumab 4 Cyclophosphamide 4 olaparib 3 liposomal doxorubicin 3 fludarabine 3 ribociclib 2 palbociclib 2 mirvetuximab soravtansine 2 Topotecan 2 Nivolumab 2 Letrozole 2 Fulvestrant 2 Blood Specimen Collection 2 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pegfilgrastim 1 niraparib 1 lenvatinib 1 isoquercitrin 1 fludarabine phosphate 1 durvalumab 1 cemiplimab 1 abemaciclib 1 Tinzaparin 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 SLC25A33 protein, human 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Carcinoma, Ovarian Epithelial × Epirubicin × Clear all

NCT03025477 2021-02-11

CHIMOVIP

Groupe Hospitalier Diaconesses Croix Saint-Simon

Phase 2 Recruiting

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡